Approximately one-half of advanced (unresectable or metastatic) melanomas harbor a
mutation in the BRAF gene, with V600E being the most common mutation. Targeted therapy …

Melanoma is a cancer that exhibits one of the most aggressive and heterogeneous features.
The incidence rate escalates. A high number of clones harboring various mutations …

Abstract Purpose of Review Immunohistochemistry is an integral technique for tissue-based
diagnostics and biomarker detection with broad worldwide adoption. Advances in core …

Strides in melanoma surveillance, detection, and treatment continue to be made. The
American Joint Committee on Cancer Eighth Edition Cancer Staging System has improved …

Objective The objective of this systematic review with meta‐analysis was to critically
evaluate the available data on sensitivity and specificity of IHC compared with molecular …

Validation of immunohistochemistry (IHC) assays is a subject that is of great importance to
clinical practice as well as basic research and clinical trials. When applied to clinical practice …

In the recent decade, cutting edge molecular and proteomic analysis platforms
revolutionized biomarkers discovery in cancers. Melanoma is the prototype with over 51,100 …

Finding the best technique to identify BRAF mutations with a high sensitivity and specificity is
mandatory for accurate patient selection for target therapy. BRAF mutation frequency ranges …

Background Although immunohistochemistry (IHC) along with molecular tests has been
investigated in ameloblastoma for BRAF V600E detection, VE1 IHC has not been studied in …

Abstract BRAF p. V600E mutations are detected in greater than 50% of pediatric
Langerhans cell histiocytosis (LCH) lesions. However, the use of mutation‐specific BRAF …